BRIDGEWATER, N.J., Sept. 14, 2015 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the needs of patients with rare diseases today reported new nontuberculous mycobacteria (NTM) lung disease information and a pharmacokinetic analysis of ARIKAYCE™ (liposomal amikacin for inhalation) will be presented at the 2015 joint meeting of the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and the International Congress of Chemotherapy and Infection (ICC). ICAAC/ICC 2015 is taking place in San Diego, California from September 17-21.
Summarized below are the poster titles and presentation times. Full abstracts can be found on the ICAAC website at http://www.icaac.org/.
Poster Title: Pharmacokinetic (PK) Evaluation of Liposomal Amikacin for Inhalation (LAI) in Patients with Treatment-refractory Nontuberculous Mycobacteria (NTM) Lung Infection
Lead Author: C. Rubino
Poster Number: A-012
Date: Friday, September 18, 2015
Session Time: 12:00-2:00 PM
Session Title: Clinical Pharmacology of Antiviral and Antituberculosis Agents
Poster Title: Nontuberculous Mycobacteria Lung Infections: Increasing Incidence of Diagnosis in Medicare Patients at a US Health Plan
Lead Author: K. Abraham
Poster Number: C-669
Date: Saturday, September 19, 2015
Session Time: 11:00 AM-1:00 PM PT
Session Title: Trends in Antimicrobial Resistance and Epidemiology of Streptococci, Enterococci and some Miscellaneous Bacteria
The posters will be made available on the company’s website after presentation at the meeting.
About Insmed
Insmed Incorporated is a global biopharmaceutical company focused on the needs of patients with rare diseases. The company is advancing a global phase 3 clinical study of ARIKAYCE™ (liposomal amikacin for inhalation) in nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that can lead to progressive inflammation and lung damage. There are no currently approved treatments for NTM in the United States or European Union (EU). In the EU, the company has filed a marketing authorization application seeking approval of ARIKAYCE for use in patients with NTM, as well as in cystic fibrosis patients with Pseudomonas aeruginosa lung infections. Insmed’s earlier-stage pipeline includes INS1009, a nebulized prodrug formulation of treprostinil that the company is developing for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. To complement its internal research, Insmed actively seeks in-licensing opportunities for a broad range of rare diseases. For more information visit www.insmed.com.